Global Pre-Filled Heparin Lock Syringe Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Pre-Filled Heparin Lock Syringe Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Heparin is used to keep the venous catheter unobstructed. Heparin helps to keep blood flowing smoothly and prevent coagulation in the catheter by making a natural substance (anticoagulant protein) in your body work better. The research object of this report is heparin (ordinary heparin), excluding heparin sodium, heparin calcium and low molecular weight heparin.

Pre-filled heparin lock syringe contains heparin solution, which is used to treat and reduce the risk of blood occlusion, while keeping the indwelling venous access device unobstructed. Pre-filled heparin lock syringe provides a reliable, cost-effective alternative to vial-based rinsing systems. In addition, pre-filled heparin lock syringe can effectively help reduce the risk of medication errors and reduce waste disposal.

Market Overview:

The latest research study on the global Pre-Filled Heparin Lock Syringe market finds that the global Pre-Filled Heparin Lock Syringe market reached a value of USD 88.83 million in 2022. It’s expected that the market will achieve USD 167.47 million by 2028, exhibiting a CAGR of 11.15% during the forecast period.

In order to reduce cross-infection in hospital and solve the problem of convenient medication, pre-filled heparin lock syringe has become a popular way. In addition, some studies have found that infections caused by novel coronavirus show changes in coagulation process, such as venous thromboembolism (VTE) and disseminated intravascular coagulation (DIC). And studies have shown that this coagulopathy is related to mortality to some extent. Anticoagulants can help reduce the mortality of hospitalized patients, which is expected to help the market growth of pre-filled heparin lock syringe.

In order to curb the COVID-19 epidemic, most countries have introduced many policies, including border blockade and social distancing. The epidemic prevention and control measures will affect the flow of people and activities, and in turn affect logistics, making the production of manufacturing, especially labor-intensive industries, affected by the supply of raw materials and labor shortages.

For the Pre-filled heparin lock syringe industry, the blockade policy will affect the supply of raw materials and export trade of products. The social distancing policy may have a great impact on the production of products, especially for some small factories, they will spend more money to maintain production during the epidemic, and factories may face the risk of closure in some areas. With the gradual control of the epidemic, some factories began to resume operation. However, while operating production, enterprises need to protect the life and health of employees, such as purchasing masks, disinfectants and other epidemic prevention materials, disinfecting the working environment before and after the production, and testing the body temperature of employees every day to ensure the health of employees. These measures will increase the production cost of enterprises and affect the development of enterprises.

However, in the long run, the COVID-19 epidemic will cause more production plants to start using more automated production lines, so as to avoid the impact of the pandemic on the industry. In addition, the application of Internet of Things technology may also bring more opportunities for industry participants.

Outstanding advantages

The powerful functions and benefits of pre-filled heparin lock syringe drive consumption, which is beneficial to the development of the industry. Pre-filled syringes have been an integral part of the rapid advancements in the healthcare industry. These syringes have not only ensured easy drug delivery but also reduced the safer administration of drugs. Usage of prefilled syringes have ensured lesser number of needle stick injuries as they eliminate the hassle of preparing dosages. The biggest advantage of pre-filled heparin lock syringe is that it prevents contamination as it reduces the changes of solution touching or entering the non-sterile parts of syringe. In addition, pre-filled heparin lock syringes also eliminate the chances of any erroneous adulteration or incorrect packaging that can cause grave medical mishaps. Thus, the paramount importance to patient safety is also projected boost the demand for pre-filled heparin lock syringes in the coming years. The prefilled syringes reduce dosing errors, increase patient compliance, increase dosing accuracy, convenience, safety and reduce the time of stays in healthcare centers. Increasing government funding for research in advanced medical treatment and target-specific delivery with concern to safety of patients is expected to drive the revenue growth of global pre-filled heparin lock syringe market. Overall, it can be said that all the advantages of pre-filled heparin lock syringe are the driving force for the development of the industry and have a beneficial impact on the industry.

Comparatively high one-time cost

The cost of the innovative and technologically developed products in the market is relatively high as compared to the conventional syringes. This makes it unaffordable for low-income and middle-income countries. Factors such as low manufacturing volume, high start-up cost, and additional safety features increase the cost of devices. For instance, according to a study in Thailand, it was concluded that reusable syringes are 36% cheaper than disposable. Hence, this factor would affect the market negatively. However, prices of pre-filled heparin lock syringes are expected to decrease during forecast period due to entry of new manufacturers and pricing pressure. Hence, high onetime cost is likely to have a minute effect on the market.

Region Overview:

Geographically, North America held the largest market share – 54.5% in 2022.

Company Overview:

Becton Dickinson is one of the major players operating in the Pre-Filled Heparin Lock Syringe market, holding a share of 34.96% in 2023.

Becton Dickinson

Becton, Dickinson and Company is a global medical technology company engaged principally in the development, manufacture, and sale of medical devices, instrument systems, and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public.

B. Braun

B. Braun Medical, Inc. manufactures medical products. The Company offers admixture, dialysis, infusion therapy, duplex and premixed drugs, infusion pump systems, needle-free systems, and pain management products.

Segmentation Overview:

By type, 5ml Syringe Size segment accounted for the largest share of market in 2022.

Application Overview:

The market's largest segment by application is the segment Hospitals, with a market share of 74.29% in 2022.

Key Companies in the global Pre-Filled Heparin Lock Syringe market covered in Chapter 3:

B. Braun
Medefil, Inc.
Troikaa
Becton Dickinson
McKesson
Excelsior Medical

In Chapter 4 and Chapter 14.2, on the basis of types, the Pre-Filled Heparin Lock Syringe market from 2018 to 2029 is primarily split into:

3ml Syringe Size
5ml Syringe Size
10ml Syringe Size

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Pre-Filled Heparin Lock Syringe market from 2018 to 2029 covers:

Hospitals
Outpatient Clinics
Homecare Settings
Pharmaceuticals Company

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)